Investors
Shifting dermatitis monitoring from reactive to proactive by 72+ hours.
7M
radiation therapy patients annually
95%
develop some grade of radiation dermatitis
20%
develop serious complications
The problem
Today, dermatitis monitoring is reactive — care teams wait for visible skin damage before intervening. That delay means complications progress further than they need to, driving up hospitalization, nursing burden, and treatment interruptions.
Traction
Product
2 patent-pending patch prototypes, bench testing and algorithm development underway
Funding & mentorship
CCEI Demo Day, Startup Westport, non-dilutive funding
The ask
To make ChromaShield a reality in our healthcare, we're raising $490,000 for anticipated launch in 2029 including manufacturing-ready R&D, 2 clinical studies, FDA establishment and 510(k) submission, and international IP filing.
Neha Shanavas, Charli Hughes, Suma Dendi
Co-founders, ChromaShield
Interested in ChromaShield?
Reach out and we'll follow up directly, including access to our pitch deck.
Contact us